oxybutynin has been researched along with Cancer Pain in 8 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Cancer Pain: Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 7.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| " The absorption rate constant was 0." | 5.43 | Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ( Bista, SR; Hardy, J; Haywood, A; Hennig, S; Norris, R, 2016) |
| "The objective of this study was to evaluate the influence of cancer cachexia on pain control in cancer patients receiving a transdermal fentanyl patch (FP) and to investigate whether dry skin was a factor related to cancer cachexia and uncontrolled pain." | 3.96 | Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch. ( Chiba, T; Kimura, S; Kudo, K; Tairabune, T; Takahashi, H; Ueda, H, 2020) |
| "In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated." | 2.90 | Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ( Bardenheuer, HJ; Burhenne, J; Geist, MJP; Mikus, G; Skopp, G; Ziesenitz, VC, 2019) |
| "Treatment directed towards painful metastases must be considered." | 2.66 | Breakthrough cancer pain in 2020. ( Klepstad, P; Løhre, ET; Thronæs, M, 2020) |
| "Its goal was to see how a transdermal fentanyl patch combined with accelerated recovery after surgery (ERAS) affected the treatment efficacy and analgesic effect of liver cancer, as well as to help patients with liver cancer choose the right analgesic treatment and nursing mode." | 1.72 | Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer. ( Fang, S; Lu, G; Xiao, H; Zhu, H, 2022) |
| " The absorption rate constant was 0." | 1.43 | Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ( Bista, SR; Hardy, J; Haywood, A; Hennig, S; Norris, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Xiao, H | 1 |
| Lu, G | 1 |
| Fang, S | 1 |
| Morikawa, N | 1 |
| Kasahara, Y | 1 |
| Takahashi, Y | 1 |
| Nishikura, K | 1 |
| Nishihara, M | 1 |
| Geist, MJP | 1 |
| Ziesenitz, VC | 1 |
| Bardenheuer, HJ | 1 |
| Burhenne, J | 1 |
| Skopp, G | 1 |
| Mikus, G | 1 |
| Løhre, ET | 1 |
| Thronæs, M | 1 |
| Klepstad, P | 1 |
| Chiba, T | 1 |
| Takahashi, H | 1 |
| Tairabune, T | 1 |
| Kimura, S | 1 |
| Ueda, H | 1 |
| Kudo, K | 1 |
| Kuip, EJM | 1 |
| Oldenmenger, WH | 1 |
| Thijs-Visser, MF | 1 |
| de Bruijn, P | 1 |
| Oosten, AW | 1 |
| Oomen-de Hoop, E | 1 |
| Koolen, SLW | 1 |
| Van der Rijt, CCD | 1 |
| Mathijssen, RHJ | 1 |
| Mercadante, S | 1 |
| Masedu, F | 1 |
| Valenti, M | 1 |
| Aielli, F | 1 |
| Bista, SR | 1 |
| Haywood, A | 1 |
| Hardy, J | 1 |
| Norris, R | 1 |
| Hennig, S | 1 |
1 review available for oxybutynin and Cancer Pain
| Article | Year |
|---|---|
Breakthrough cancer pain in 2020.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Fentanyl; Humans; Neoplasm Metastasis; Pain Mana | 2020 |
2 trials available for oxybutynin and Cancer Pain
| Article | Year |
|---|---|
Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Cytochrome P-450 CYP3A; Female; Fentanyl; | 2019 |
Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Breakthr | 2019 |
5 other studies available for oxybutynin and Cancer Pain
| Article | Year |
|---|---|
Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Enhanced Recovery After Surgery; Fentany | 2022 |
Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Drug Interactions; Drug Sub | 2019 |
Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Topics: Aged; Analgesics, Opioid; Cachexia; Cancer Pain; Female; Fentanyl; Humans; Male; Middle Aged; Morphi | 2020 |
Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Body Mass Index; Cancer Pain; Cohort Studies; F | 2018 |
Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Female; | 2016 |